<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Significant number of psychotic episodes in the aftermath of Spanish flu pandemic has highlighted the possibility of increasing incidence of schizophrenic disorders in subjects infected with the SARS-COV-2
 <sup>
  <xref ref-type="bibr" rid="CR169">169</xref>
 </sup>. High levels of coronavirus immunoreactivity in subjects with recent onset of psychotic episodes as well as the serious neuropsychiatric complications including auditory and visual hallucinations as well as severe delusions have been reported in COVID-19 patients
 <sup>
  <xref ref-type="bibr" rid="CR120">120</xref>,
  <xref ref-type="bibr" rid="CR170">170</xref>,
  <xref ref-type="bibr" rid="CR171">171</xref>
 </sup>. Although neurodevelopmental origins of schizophrenia are generally accepted, other aetiological factors such as direct effect of a viral neuroinfection or indirect effect of immune aberrations occurring in adult subjects cannot be excluded
 <sup>
  <xref ref-type="bibr" rid="CR172">172</xref>
 </sup>. Schizophrenia is also considered as a neurodegenerative illness in adulthood, with neuronal shrinkage and loss, oligodendrocyte damage, alterations in synaptic connectivity, all likely associated with cognitive impairments
 <sup>
  <xref ref-type="bibr" rid="CR162">162</xref>â€“
  <xref ref-type="bibr" rid="CR173">173</xref>
 </sup>. Although there are no evidence directly linking COVID-19 with the risk of schizophrenia, frequent occurrence of psychotic episodes highlights the need for further, more detailed investigations.
</p>
